{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:59:47Z","timestamp":1760122787362},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00467-018-4076-2","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T06:34:48Z","timestamp":1536561288000},"page":"2295-2309","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biologics for childhood systemic vasculitis"],"prefix":"10.1007","volume":"34","author":[{"given":"Keiji","family":"Akamine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilynn","family":"Punaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"4076_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214\u2013223","journal-title":"N Engl J Med"},{"key":"4076_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00467-016-3490-6","volume":"32","author":"AM Kouri","year":"2017","unstructured":"Kouri AM, Andreoli SP (2017) Clinical presentation and outcome of pediatric ANCA-associated glomerulonephritis. Pediatr Nephrol 32:449\u2013455","journal-title":"Pediatr Nephrol"},{"key":"4076_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1546-0096-9-12","volume":"9","author":"N Arulkumaran","year":"2011","unstructured":"Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey CD, Salama AD (2011) Long-term outcome of paediatric patients with ANCA vasculitis. Pediatr Rheumatol Online J 9:12","journal-title":"Pediatr Rheumatol Online J"},{"key":"4076_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00467-017-3597-4","volume":"33","author":"P Brogan","year":"2018","unstructured":"Brogan P, Eleftheriou D (2018) Vasculitis update: pathogenesis and biomarkers. Pediatr Nephrol 33:187\u2013198","journal-title":"Pediatr Nephrol"},{"key":"4076_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","volume":"103","author":"ER Popa","year":"1999","unstructured":"Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW (1999) Differential B- and T-cell activation in Wegener\u2019s granulomatosis. J Allergy Clin Immunol 103:885\u2013894","journal-title":"J Allergy Clin Immunol"},{"key":"4076_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1172\/JCI0215918","volume":"110","author":"H Xiao","year":"2002","unstructured":"Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955\u2013963","journal-title":"J Clin Invest"},{"key":"4076_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1681\/ASN.2005101048","volume":"17","author":"JC Jennette","year":"2006","unstructured":"Jennette JC, Xiao H, Falk RJ (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17:1235\u20131242","journal-title":"J Am Soc Nephrol"},{"key":"4076_CR8","doi-asserted-by":"publisher","first-page":"e28626","DOI":"10.1371\/journal.pone.0028626","volume":"7","author":"MA Little","year":"2012","unstructured":"Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS (2012) Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 7:e28626","journal-title":"PLoS One"},{"key":"4076_CR9","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","volume":"44","author":"U Specks","year":"2001","unstructured":"Specks U, Fervenza FC, McDonald TJ, Hogan MC (2001) Response of Wegener\u2019s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836\u20132840","journal-title":"Arthritis Rheum"},{"key":"4076_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"4076_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","volume":"74","author":"RB Jones","year":"2015","unstructured":"Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR, European Vasculitis Society (EUVAS) (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74:1178\u20131182","journal-title":"Ann Rheum Dis"},{"key":"4076_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Pan-Thames Renal Research Group (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776\u2013784","journal-title":"Am J Kidney Dis"},{"key":"4076_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A, Jayne D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166\u20131173","journal-title":"Arthritis Care Res"},{"key":"4076_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"4076_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH, RAVE-ITN Research Group (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417\u2013427","journal-title":"N Engl J Med"},{"key":"4076_CR16","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760\u20133769","journal-title":"Arthritis Rheum"},{"key":"4076_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","volume":"53","author":"P Charles","year":"2014","unstructured":"Charles P, Neel A, Tieulie N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tcherakian C, Guillevin L, French Vasculitis Study Group (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford) 53:532\u2013539","journal-title":"Rheumatology (Oxford)"},{"key":"4076_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2215\/CJN.08821209","volume":"5","author":"EP Rhee","year":"2010","unstructured":"Rhee EP, Laliberte KA, Niles JL (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5:1394\u20131400","journal-title":"Clin J Am Soc Nephrol"},{"key":"4076_CR19","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quemeneur T, Blanchard-Delaunay C, Godmer P, Puechal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771\u20131780","journal-title":"N Engl J Med"},{"key":"4076_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"P Brogan","year":"2018","unstructured":"Brogan P, Cleary G, Kasapcopur O, Rangaraj S, Yeung R, Brunetta P, Cooper J, Pordeli P, Lehane PB (2018) OP0332 Paediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Ann Rheum Dis 77:212","journal-title":"Ann Rheum Dis"},{"key":"4076_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-016-3559-2","volume":"33","author":"LA Plumb","year":"2018","unstructured":"Plumb LA, Oni L, Marks SD, Tullus K (2018) Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol 33:25\u201339","journal-title":"Pediatr Nephrol"},{"key":"4076_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial Research Group","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial Research Group (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 352:351\u2013361","journal-title":"N Engl J Med"},{"key":"4076_CR23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/art.30394","volume":"63","author":"F Silva","year":"2011","unstructured":"Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, Spiera R, Sebastian JK, Davis JC Jr, St Clair EW, Allen NB, WJ MC, Ytterberg SR, Specks U, Wegener\u2019s Granulomatosis Etanercept Trial Research Group (2011) Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener\u2019s): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 63:2495\u20132503","journal-title":"Arthritis Rheum"},{"key":"4076_CR24","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/ard.2007.083584","volume":"67","author":"L Josselin","year":"2008","unstructured":"Josselin L, Mahr A, Cohen P, Pagnoux C, Guaydier-Souquieres G, Hayem G, Job-Deslandre C, Liferman F, Pourrat J, Guillevin L (2008) Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 67:1343\u20131346","journal-title":"Ann Rheum Dis"},{"key":"4076_CR25","doi-asserted-by":"publisher","first-page":"c89","DOI":"10.1159\/000319655","volume":"117","author":"MD Morgan","year":"2011","unstructured":"Morgan MD, Drayson MT, Savage CO, Harper L (2011) Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 117:c89\u2013c97","journal-title":"Nephron Clin Pract"},{"key":"4076_CR26","first-page":"S63","volume":"29","author":"M Menthon de","year":"2011","unstructured":"de Menthon M, Cohen P, Pagnoux C, Buchler M, Sibilia J, Detree F, Gayraud M, Khellaf M, Penalba C, Legallicier B, Mouthon L, Guillevin L (2011) Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29:S63\u2013S71","journal-title":"Clin Exp Rheumatol"},{"key":"4076_CR27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, CA MA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA, Vasculitis Clinical Research Consortium (2014) An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s). Ann Rheum Dis 73:1376\u20131379","journal-title":"Ann Rheum Dis"},{"key":"4076_CR28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/ard.2007.081661","volume":"67","author":"M Walsh","year":"2008","unstructured":"Walsh M, Chaudhry A, Jayne D (2008) Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67:1322\u20131327","journal-title":"Ann Rheum Dis"},{"key":"4076_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","volume":"45","author":"A Berti","year":"2015","unstructured":"Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C, Dagna L (2015) Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum 45:48\u201354","journal-title":"Semin Arthritis Rheum"},{"key":"4076_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DR (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396\u2013401","journal-title":"Ann Rheum Dis"},{"key":"4076_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.reuma.2014.08.005","volume":"11","author":"SA Munoz","year":"2015","unstructured":"Munoz SA, Gandino IJ, Orden AO, Allievi A (2015) Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin 11:165\u2013169","journal-title":"Reumatol Clin"},{"key":"4076_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich B, Csernok E, Gross WL (2005) Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 1051:121\u2013131","journal-title":"Ann N Y Acad Sci"},{"key":"4076_CR33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921\u20131932","journal-title":"N Engl J Med"},{"key":"4076_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00467-012-2172-2","volume":"27","author":"P Krug","year":"2012","unstructured":"Krug P, Boyer O, Balzamo E, Sidi D, Lehnert A, Niaudet P (2012) Nephrotic syndrome in Kawasaki disease: a report of three cases. Pediatr Nephrol 27:1547\u20131550","journal-title":"Pediatr Nephrol"},{"key":"4076_CR35","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135:e927\u2013e999","journal-title":"Circulation"},{"key":"4076_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","volume":"383","author":"AH Tremoulet","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383:1731\u20131738","journal-title":"Lancet"},{"key":"4076_CR37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153:833\u2013838","journal-title":"J Pediatr"},{"key":"4076_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jpeds.2014.01.020","volume":"164","author":"K Sonoda","year":"2014","unstructured":"Sonoda K, Mori M, Hokosaki T, Yokota S (2014) Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 164:1128\u20131132 e1","journal-title":"J Pediatr"},{"key":"4076_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jpeds.2010.06.014","volume":"157","author":"NF Choueiter","year":"2010","unstructured":"Choueiter NF, Olson AK, Shen DD, Portman MA (2010) Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 157:960\u2013966 e1","journal-title":"J Pediatr"},{"key":"4076_CR40","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMc1709609","volume":"377","author":"T Nozawa","year":"2017","unstructured":"Nozawa T, Imagawa T, Ito S (2017) Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki\u2019s disease. N Engl J Med 377:1894\u20131896","journal-title":"N Engl J Med"},{"key":"4076_CR41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0140-6736(89)91910-7","volume":"2","author":"DY Leung","year":"1989","unstructured":"Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2:1298\u20131302","journal-title":"Lancet"},{"key":"4076_CR42","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/CIRCULATIONAHA.111.072769","volume":"125","author":"Y Lee","year":"2012","unstructured":"Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, Fishbein MC, Lehman TJ, Arditi M (2012) Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 125:1542\u20131550","journal-title":"Circulation"},{"key":"4076_CR43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00467-008-1088-3","volume":"24","author":"R Hijazi","year":"2009","unstructured":"Hijazi R, Chandar J, Nwobi O, Muneeruddin S, Zilleruelo G, Abitbol CL (2009) Renal manifestations in toddlers with Takayasu\u2019s arteritis and malignant hypertension. Pediatr Nephrol 24:1227\u20131230","journal-title":"Pediatr Nephrol"},{"key":"4076_CR44","doi-asserted-by":"publisher","unstructured":"Tombetti E, Mason JC (2018) Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology (Oxford). \n                    https:\/\/doi.org\/10.1093\/rheumatology\/key040","DOI":"10.1093\/rheumatology\/key040"},{"key":"4076_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12969-016-0082-8","volume":"14","author":"D Eleftheriou","year":"2016","unstructured":"Eleftheriou D, Brogan PA (2016) Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol Online J 14:26","journal-title":"Pediatr Rheumatol Online J"},{"key":"4076_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1536\/jhj.41.15","volume":"41","author":"Y Seko","year":"2000","unstructured":"Seko Y (2000) Takayasu arteritis: insights into immunopathology. Jpn Heart J 41:15\u201326","journal-title":"Jpn Heart J"},{"key":"4076_CR47","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, Vasculitis Clinical Research Consortium (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 69:846\u2013853","journal-title":"Arthritis Rheumatol"},{"key":"4076_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/BOR.0000000000000004","volume":"26","author":"A Clifford","year":"2014","unstructured":"Clifford A, Hoffman GS (2014) Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 26:7\u201315","journal-title":"Curr Opin Rheumatol"},{"key":"4076_CR49","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","volume":"11","author":"C Comarmond","year":"2012","unstructured":"Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, Cacoub P, Saadoun D (2012) Anti TNF-alpha in refractory Takayasu\u2019s arteritis: cases series and review of the literature. Autoimmun Rev 11:678\u2013684","journal-title":"Autoimmun Rev"},{"key":"4076_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jpeds.2008.04.049","volume":"153","author":"G Filocamo","year":"2008","unstructured":"Filocamo G, Buoncompagni A, Viola S, Loy A, Malattia C, Ravelli A, Martini A (2008) Treatment of Takayasu\u2019s arteritis with tumor necrosis factor antagonists. J Pediatr 153:432\u2013434","journal-title":"J Pediatr"},{"key":"4076_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","volume":"45","author":"MC Park","year":"2006","unstructured":"Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis. Rheumatology (Oxford) 45:545\u2013548","journal-title":"Rheumatology (Oxford)"},{"key":"4076_CR52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348\u2013354","journal-title":"Ann Rheum Dis"},{"key":"4076_CR53","first-page":"S10","volume":"24","author":"MC Park","year":"2006","unstructured":"Park MC, Park YB, Jung SY, Lee KH, Lee SK (2006) Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu\u2019s arteritis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol 24:S10\u2013S16","journal-title":"Clin Exp Rheumatol"},{"key":"4076_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/ard.2011.153007","volume":"71","author":"BF Hoyer","year":"2012","unstructured":"Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75\u201379","journal-title":"Ann Rheum Dis"},{"key":"4076_CR55","doi-asserted-by":"publisher","unstructured":"Pazzola G, Muratore F, Pipitone N, Salvarani C (2018) Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature: reply. Rheumatology (Oxford). \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex494","DOI":"10.1093\/rheumatology\/kex494"},{"key":"4076_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jpeds.2007.04.062","volume":"151","author":"F Yalcinkaya","year":"2007","unstructured":"Yalcinkaya F, Ozcakar ZB, Kasapcopur O, Ozturk A, Akar N, Bakkaloglu A, Arisoy N, Ekim M, Ozen S (2007) Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. J Pediatr 151:675\u2013678","journal-title":"J Pediatr"},{"key":"4076_CR57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrrheum.2017.68","volume":"13","author":"S Ozen","year":"2017","unstructured":"Ozen S (2017) The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol 13:381\u2013386","journal-title":"Nat Rev Rheumatol"},{"key":"4076_CR58","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911\u2013920","journal-title":"N Engl J Med"},{"key":"4076_CR59","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921\u2013931","journal-title":"N Engl J Med"},{"key":"4076_CR60","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","volume":"38","author":"I Meyts","year":"2018","unstructured":"Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38:569\u2013578","journal-title":"J Clin Immunol"},{"key":"4076_CR61","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","volume":"48","author":"D Eleftheriou","year":"2009","unstructured":"Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, Dolezalova P, Ozen S, Pilkington C, Woo P, Klein N, Dillon MJ, Brogan PA (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48:978\u2013986","journal-title":"Rheumatology (Oxford)"},{"key":"4076_CR62","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3109\/14397595.2015.1014153","volume":"27","author":"Y Seri","year":"2017","unstructured":"Seri Y, Shoda H, Hanata N, Nagafuchi Y, Sumitomo S, Fujio K, Yamamoto K (2017) A case of refractory polyarteritis nodosa successfully treated with rituximab. Mod Rheumatol 27:696\u2013698","journal-title":"Mod Rheumatol"},{"key":"4076_CR63","doi-asserted-by":"publisher","first-page":"e000446","DOI":"10.1136\/rmdopen-2017-000446","volume":"3","author":"A Saunier","year":"2017","unstructured":"Saunier A, Issa N, Vandenhende MA, Morlat P, Doutre MS, Bonnet F (2017) Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach? RMD Open 3:e000446","journal-title":"RMD Open"},{"key":"4076_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00467-003-1376-x","volume":"19","author":"BJ Heijden van der","year":"2004","unstructured":"van der Heijden BJ, van Dijk PC, Verrier-Jones K, Jager KJ, Briggs JD (2004) Renal replacement therapy in children: data from 12 registries in Europe. Pediatr Nephrol 19:213\u2013221","journal-title":"Pediatr Nephrol"},{"key":"4076_CR65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12026-016-8827-5","volume":"65","author":"R Fenoglio","year":"2017","unstructured":"Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, Beltrame G, Roccatello D (2017) Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res 65:186\u2013192","journal-title":"Immunol Res"},{"key":"4076_CR66","doi-asserted-by":"publisher","first-page":"619218","DOI":"10.1155\/2014\/619218","volume":"2014","author":"T Pindi Sala","year":"2014","unstructured":"Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Esteve E, Marie B, Taoufik Y, Delfraissy JF, Lazure T, Lambotte O (2014) Successful outcome of a corticodependent henoch-schonlein purpura adult with rituximab. Case Rep Med 2014:619218","journal-title":"Case Rep Med"},{"key":"4076_CR67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/RHU.0b013e31819bca9e","volume":"15","author":"S Nobile","year":"2009","unstructured":"Nobile S, Catassi C, Felici L (2009) Herpes zoster infection followed by Henoch-Schonlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 15:101","journal-title":"J Clin Rheumatol"},{"key":"4076_CR68","first-page":"S106","volume":"24","author":"TN Duffy","year":"2006","unstructured":"Duffy TN, Genta M, Moll S, Martin PY, Gabay C (2006) Henoch Schonlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 24:S106","journal-title":"Clin Exp Rheumatol"},{"key":"4076_CR69","first-page":"2812980","volume":"2016","author":"JJ LaConti","year":"2016","unstructured":"LaConti JJ, Donet JA, Cho-Vega JH, Sussman DA, Ascherman D, Deshpande AR (2016) Henoch-Schonlein purpura with adalimumab therapy for ulcerative colitis: a case report and review of the literature. Case Rep Rheumatol 2016:2812980","journal-title":"Case Rep Rheumatol"},{"key":"4076_CR70","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","volume":"51","author":"MJ Guerry","year":"2012","unstructured":"Guerry MJ, Brogan P, Bruce IN, D\u2019Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR (2012) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51:634\u2013643","journal-title":"Rheumatology (Oxford)"},{"key":"4076_CR71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3899\/jrheum.150376","volume":"43","author":"L McGeoch","year":"2016","unstructured":"McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, Cabral DA, Carette S, Cox GP, Dhindsa N, Dipchand CS, Fifi-Mah A, Goulet M, Khalidi N, Khraishi MM, Liang P, Milman N, Pineau CA, Reich HN, Samadi N, Shojania K, Taylor-Gjevre R, Towheed TE, Trudeau J, Walsh M, Yacyshyn E, Pagnoux C, Canadian Vasculitis Research Network (2016) CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 43:97\u2013120","journal-title":"J Rheumatol"},{"key":"4076_CR72","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/art.39729","volume":"68","author":"DA Cabral","year":"2016","unstructured":"Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, Twilt M, Benseler SM, Campillo S, Charuvanij S, Dancey P, Eberhard BA, Elder ME, Hersh A, Higgins GC, Huber AM, Khubchandani R, Kim S, Klein-Gitelman M, Kostik MM, Lawson EF, Lee T, Lubieniecka JM, McCurdy D, Moorthy LN, Morishita KA, Nielsen SM, O\u2019Neil KM, Reiff A, Ristic G, Robinson AB, Sarmiento A, Shenoi S, Toth MB, Van Mater HA, Wagner-Weiner L, Weiss JE, White AJ, Yeung RS, ARChiVe Investigators Network within the PedVas Initiative (2016) Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener\u2019s): an ARChiVe cohort study. Arthritis Rheumatol 68:2514\u20132526","journal-title":"Arthritis Rheumatol"},{"key":"4076_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-017-0191-z","volume":"15","author":"C Westwell-Roper","year":"2017","unstructured":"Westwell-Roper C, Lubieniecka JM, Brown KL, Morishita KA, Mammen C, Wagner-Weiner L, Yen E, Li SC, O\u2019Neil KM, Lapidus SK, Brogan P, Cimaz R, Cabral DA, for ARChiVe Investigators Network within the PedVas initiative (2017) Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. Pediatr Rheumatol Online J 15:61","journal-title":"Pediatr Rheumatol Online J"},{"key":"4076_CR74","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/art.34362","volume":"64","author":"L Lightstone","year":"2012","unstructured":"Lightstone L (2012) The landscape after LUNAR: rituximab\u2019s crater-filled path. Arthritis Rheum 64:962\u2013965","journal-title":"Arthritis Rheum"},{"key":"4076_CR75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P, Kahn S, Obermoser G, Blankenship D, Wakeland E, Nassi L, Gotte A, Punaro M, Liu YJ, Banchereau J, Rossello-Urgell J, Wright T, Pascual V (2016) Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165:551\u2013565","journal-title":"Cell"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4076-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4076-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4076-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T23:14:46Z","timestamp":1571181286000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4076-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4076"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4076-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"8 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}